We are live on
!
Find out more
Federated Hermes Portfolio holdings
AUM
$69.6B
1-Year Est. Return
42.52%
This Fund
S&P 500
This Quarter
Est. Return
+13.69%
1 Year Est. Return
+42.52%
3 Year Est. Return
+132.48%
5 Year Est. Return
+152.58%
10 Year Est. Return
+652.43%
AUM
$53.1B
AUM Growth
+$6.76B
(+15%)
Cap. Flow
+$2.33B
Cap. Flow
% of AUM
4.39%
Top 10 Holdings %
Top 10 Hldgs %
14.65%
Holding
2,220
New
169
Increased
729
Reduced
1,033
Closed
165
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Zscaler
ZS
|
+$222M |
| 2 |
Palantir
PLTR
|
+$221M |
| 3 |
Alphabet (Google) Class A
GOOGL
|
+$213M |
| 4 |
FirstEnergy
FE
|
+$189M |
| 5 |
Broadcom
AVGO
|
+$174M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$383M |
| 2 |
Philip Morris
PM
|
+$280M |
| 3 |
Entergy
ETR
|
+$207M |
| 4 |
Paychex
PAYX
|
+$206M |
| 5 |
Gilead Sciences
GILD
|
+$201M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 22.81% |
| 2 | Healthcare | 14.57% |
| 3 | Financials | 13.43% |
| 4 | Industrials | 10.29% |
| 5 | Consumer Discretionary | 9.94% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1451
CVS Health
CVS
$119B
| $266K | ﹤0.01% |
3,858
-540
| -12% | -$35.4K |
|
1452
CG Oncology
CGON
$7B
| $265K | ﹤0.01% |
10,200
+1,700
| +20% | +$41K |
|
1453
Kratos Defense & Security Solutions
KTOS
$10.1B
| $263K | ﹤0.01% |
+5,661
| New | +$205K |
|
1454
Sunstone Hotel Investors
SHO
$2.08B
| $260K | ﹤0.01% |
30,000
+16,800
| +127% | +$145K |
|
1455
Amphastar Pharmaceuticals
AMPH
$931M
| $258K | ﹤0.01% |
11,224
-573,891
| -98% | -$14.2M |
|
|
PCH
1456
DELISTED
PotlatchDeltic
PCH
| $256K | ﹤0.01% |
6,677
-112
| -2% | -$4.4K |
|
1457
Oneok
OKE
$59.7B
| $255K | ﹤0.01% |
3,120
+383
| +14% | +$31.9K |
|
|
HES
1458
DELISTED
Hess
HES
| $254K | ﹤0.01% |
1,831
-58
| -3% | -$7.83K |
|
|
IAS
1459
DELISTED
Integral Ad Science
IAS
| $249K | ﹤0.01% |
30,000
+3,000
| +11% | +$22.9K |
|
1460
Arthur J. Gallagher & Co
AJG
$66.7B
| $248K | ﹤0.01% |
775
-343
| -31% | -$113K |
|
1461
Relay Therapeutics
RLAY
$4.26B
| $246K | ﹤0.01% |
71,217
-25,096
| -26% | -$74.6K |
|
1462
Ralph Lauren
RL
$21B
| $244K | ﹤0.01% |
889
+226
| +34% | +$55.9K |
|
1463
PG&E
PCG
$39.5B
| $242K | ﹤0.01% |
17,389
+7,749
| +80% | +$126K |
|
1464
NXP Semiconductors
NXPI
$57B
| $240K | ﹤0.01% |
1,099
-18
| -2% | -$3.52K |
|
|
WSR
1465
DELISTED
Whitestone REIT
WSR
| $233K | ﹤0.01% |
18,662
+1,014
| +6% | +$12.9K |
|
1466
Neumora Therapeutics
NMRA
$278M
| $230K | ﹤0.01% |
314,119
+29,543
| +10% | +$22.4K |
|
1467
Haemonetics
HAE
$4.78B
| $228K | ﹤0.01% |
3,062
+72
| +2% | +$4.77K |
|
1468
Concentrix
CNXC
$1.72B
| $227K | ﹤0.01% |
4,294
+1,930
| +82% | +$102K |
|
1469
Aon
AON
$74.2B
| $227K | ﹤0.01% |
635
-324
| -34% | -$117K |
|
1470
Synopsys
SNPS
$89.1B
| $226K | ﹤0.01% |
440
-5
| -1% | -$2.33K |
|
1471
Hilton Grand Vacations
HGV
$3.41B
| $224K | ﹤0.01% |
5,391
-484
| -8% | -$18.3K |
|
1472
Mineralys Therapeutics
MLYS
$2.3B
| $224K | ﹤0.01% |
16,528
+4,577
| +38% | +$66.3K |
|
|
ECHO
1473
EchoStar
ECHO
$25.1B
| $223K | ﹤0.01% |
8,068
+1,576
| +24% | +$34.6K |
|
|
HBI
1474
DELISTED
Hanesbrands
HBI
| $223K | ﹤0.01% |
48,625
+31,202
| +179% | +$151K |
|
1475
Old Second Bancorp
OSBC
$1.28B
| $222K | ﹤0.01% |
12,515
+113
| +0.9% | +$1.84K |
|
Similar funds
Federated Hermes's Q2 2025 Portfolio in Review
As of Q2 2025, Federated Hermes held 2,220 positions worth $53.1B, up 15% from $46.4B the previous quarter. Its ten largest holdings account for 15% of the portfolio.
Federated Hermes deployed $2.33B of net new capital in Q2 2025, opening 169 new positions and adding to 729 existing holdings. Its largest new stake was Genuine Parts: 882,160 shares worth $107M.
By sector, the portfolio is most concentrated in Technology at 23% of assets, up from 20% a quarter earlier, followed by Healthcare and Financials.
On the sell side, the largest reduction was Bristol-Myers Squibb, an estimated $383M trimmed.
- Federated Hermes's largest Q2 2025 buy was Genuine Parts: 882,160 shares worth $107M.
- Federated Hermes added most to Zscaler in Q2 2025, an estimated $222M increase.
- Federated Hermes's biggest Q2 2025 reduction was Bristol-Myers Squibb, cutting an estimated $383M.
- Federated Hermes fully exited Regulus Therapeutics in Q2 2025, selling an estimated $39.2M.
- Federated Hermes's ten largest holdings make up 15% of its $53.1B portfolio in Q2 2025.
- Federated Hermes opened 169 new positions and closed 165 in Q2 2025.
- Federated Hermes's portfolio value rose 15% quarter-over-quarter to $53.1B.
Based on Federated Hermes's 13F filing for Q2 2025, filed 13 Aug 2025.